4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
MoonLake Immunotherapeutics (MLTX) operates in the Biotechnology industry and is headquartered in Zug, Switzerland with about 130 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, MLTX reported $0M in revenue and ($227M) in net income.
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($245M) | ($143M) | ($54M) | ($65M) |
| Net Income | ($227M) | ($119M) | ($36M) | ($50M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($70M) | ($65M) | ($71M) | ($61M) | ($48M) | — |
| Net Income | ($70M) | ($62M) | ($70M) | ($55M) | ($40M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $424M | $478M | $526M | $77M | — |
| Total Liabilities | $120M | $24M | $13M | $8M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MLTX viewer.
About TickerBase · Data methodology & sources